Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 7, 2024Current OncologyOpen Access

Incidence of Ophthalmological Complications in NF-1 Patients Treated with MEK Inhibitors

View Full Paper
Ask AI
Bookmark
Share

Authors

LHLena HummelMethodist HospitalMAMay AmeriBaylor College of MedicineSAShaikha AlqahtaniDuke University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Hummel et al. (2024) studied this question.

synapsesocial.com/papers/68e6b291b6db643587633db7https://doi.org/10.3390/curroncol31050199
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations2012 · 2,842 citations
  2. 2Subretinal Fluid Associated With MEK Inhibitor Use in the Treatment of Systemic Cancer2016 · 86 citations
  3. 3Novel molecular targeted therapies for patients with neurofibromatosis type 1 with inoperable plexiform neurofibromas: a comprehensive review2021 · 59 citations
  4. 4The Use of MEK Inhibitors in Neurofibromatosis Type 1–Associated Tumors and Management of Toxicities2020 · 115 citations
  5. 5OCULAR ADVERSE EVENTS ASSOCIATED WITH MEK INHIBITORS2019 · 118 citations